SWS Medical(SH:688410) Xin Lang Cai Jing·2025-10-30 03:07Core Viewpoint - The company, Chongqing Shanwaishan Blood Purification Technology Co., Ltd., has shown significant growth in revenue and net profit for the first nine months of 2025, indicating strong operational performance in the medical device sector [2]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 584 million yuan, representing a year-on-year growth of 39.79% [2]. - The net profit attributable to the parent company reached 104 million yuan, marking a year-on-year increase of 68.68% [2]. Stock Performance - As of October 30, the company's stock price decreased by 2.05%, trading at 16.26 yuan per share, with a total market capitalization of 5.225 billion yuan [1]. - Year-to-date, the stock price has increased by 47.02%, with a 11.91% rise over the last five trading days [1]. Shareholder Information - As of September 30, the number of shareholders increased to 10,300, a rise of 26.20% compared to the previous period [2]. - The average number of circulating shares per shareholder decreased by 20.76% to 22,805 shares [2]. Dividend Distribution - Since its A-share listing, the company has distributed a total of 104 million yuan in dividends [3]. Institutional Holdings - As of September 30, 2025, among the top ten circulating shareholders, Penghua Medical Technology Stock A is the fourth largest with 5.182 million shares, marking a new entry [3]. - Bosera Healthcare Mixed A remains the sixth largest shareholder, holding 3.257 million shares, unchanged from the previous period [3].